Effects of intermedin on proliferation, apoptosis and the expression of OPG/RANKL/M-CSF in the MC3T3-E1 osteoblast cell line

Ren,Hongfei; Ren,Hongyu; Li,Xue; Yu,Dongdong; Mu,Shuai; Chen,Zhiguang; Fu,Qin

doi:10.3892/mmr.2015.4328

Effects of intermedin on proliferation, apoptosis and the expression of OPG/RANKL/M-CSF in the MC3T3-E1 osteoblast cell line

Authors:
- Hongfei Ren
- Hongyu Ren
- Xue Li
- Dongdong Yu
- Shuai Mu
- Zhiguang Chen
- Qin Fu
View Affiliations

Affiliations: Department of Orthopedic Surgery, Shengjing Hospital of China Medical University, Shenyang, Liaoning 110004, P.R. China, Department of Orthopedic Surgery, Gaizhou Central Hospital, Yingkou, Liaoning 115200, P.R. China, Department of Orthopedic Surgery, First Affiliated Hospital of Liaoning Medical University, Jingzhou, Liaoning 121001, P.R. China
Published online on: September 15, 2015 https://doi.org/10.3892/mmr.2015.4328
Pages: 6711-6717
Copyright: © Ren et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Bone remodeling is a vital physiological process of healthy bone tissue in humans. It is characterized by the formation of bone by osteoblasts and its resorption by osteoclasts, and the bone resorbed by osteoclasts is replaced through the differentiation and activity of osteoblasts. Imbalances in this vital process lead to pathological conditions, including osteoporosis. Intermedin (IMD) as a newly discovered peptide in the calcitonin (CT) family of peptides, which shares similar functions with CT, calcitonin gene‑related peptide and amylin in bone resorption. However, the mechanism underlying its effect remains to be elucidated. This was investigated in the present study using the osteoblastic MC3T3‑E1 cell line, which was treated with different doses of IMD (0, 1, 10 and 100 nM). Cell proliferation, apoptosis and the expression of receptor activator of NF‑κB ligand (RANKL), osteoprotegerin (OPG) and macrophage colony‑stimulating factor (M‑CSF) were measured following treatment using multiple detection techniques, including an MTT assay, flow cytometry, reverse transcription‑quantitative polymerase chain reaction and western blot analysis. The resulting data demonstrated that IMD significantly inhibited the apoptosis of MC3T3‑E1 cells induced by serum‑free culture and dexamethasone, however, no significant effects on MC3T3‑E1 cell proliferation were observed. IMD had additional functions on the MC3T3‑E1 cells, including inhibition of the expression of RANKL and M‑CSF, and promotion of the expression of OPG. Previous studies have also demonstrated that RANKL and M‑CSF are two vital factor produced by osteoblasts to promote the maturation and differentiation of osteoclasts, and it has been reported that IMD can inhibit the osteoclast formation stimulated by RANKL and M‑CSF. Together with these findings, the present study concluded that IMD reduces bone resorption by inhibiting osteoblast apoptosis, decreasing the RANKL/OPG ratio and the expression of M-CSF, and inhibiting osteoclast maturation and differentiation.

View Figures

View References

1	Roh J, Chang CL, Bhalla A, Klein C and Hsu SY: Intermedin is a calcitonin/calcitonin gene-related peptide family peptide acting through the calcitonin receptor-like receptor/receptor activity-modifying protein receptor complexes. J Biol Chem. 279:7264–7274. 2004. View Article : Google Scholar
2	Takei Y, Inoue K, Ogoshi M, Kawahara T, Bannai H and Miyano S: Identification of novel adrenomedullin in mammals: A potent cardiovascular and renal regulator. FEBS Lett. 556:53–58. 2004. View Article : Google Scholar : PubMed/NCBI
3	Chauhan M, Balakrishnan M, Yallampalli U, Endsley J, Hankins GD, Theiler R and Yallampalli C: Adrenomedullin 2/intermedin regulates HLA-G in human trophoblasts. Biol Reprod. 85:1232–1239. 2011. View Article : Google Scholar : PubMed/NCBI
4	Takahashi K, Kikuchi K, Maruyama Y, Urabe T, Nakajima K, Sasano H, Imai Y, Murakami O and Totsune K: Immunocytochemical localization of adrenomedullin 2/intermedin-like immunore-activity in human hypothalamus, heart and kidney. Peptides. 27:1383–1389. 2006. View Article : Google Scholar
5	Takahashi K, Morimoto R, Hirose T, Satoh F and Totsune K: Adrenomedullin 2/intermedin in the hypothalamo-pituitary-adrenal axis. J Mol Neurosci. 43:182–192. 2011. View Article : Google Scholar
6	Chauhan M, Yallampalli U, Dong YL, Hankins GD and Yallampalli C: Expression of adrenomedullin 2 (ADM2)/intermedin (IMD) in human placenta: Role in trophoblast invasion and migration. Biol Reprod. 81:777–783. 2009. View Article : Google Scholar : PubMed/NCBI
7	McLatchie LM, Fraser NJ, Main MJ, Wise A, Brown J, Thompson N, Solari R, Lee MG and Foord SM: RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor. Nature. 393:333–339. 1998. View Article : Google Scholar : PubMed/NCBI
8	Pan CS, Yang JH, Cai DY, Zhao J, Gerns H, Yang J, Chang JK, Tang CS and Qi YF: Cardiovascular effects of newly discovered peptide intermedin/adrenomedullin 2. Peptides. 26:1640–1646. 2005. View Article : Google Scholar : PubMed/NCBI
9	Fujisawa Y, Nagai Y, Miyatake A, Takei Y, Miura K, Shoukouji T, Nishiyama A, Kimura S and Abe Y: Renal effects of a new member of adrenomedullin family, adrenomedullin2, in rats. Eur J Pharmacol. 497:75–80. 2004. View Article : Google Scholar : PubMed/NCBI
10	Holmes D, Campbell M, Harbinson M and Bell D: Protective effects of intermedin on cardiovascular, pulmonary and renal diseases: Comparison with adrenomedullin and CGRP. Curr Protein Pept Sci. 14:294–329. 2013. View Article : Google Scholar : PubMed/NCBI
11	Granholm S, Lundberg P and Lerner UH: Expression of the calcitonin receptor, calcitonin receptor-like receptor, and receptor activity modifying proteins during osteoclast differentiation. J Cell Biochem. 104:920–933. 2008. View Article : Google Scholar : PubMed/NCBI
12	Naot D and Cornish J: The role of peptides and receptors of the calcitonin family in the regulation of bone metabolism. Bone. 43:813–818. 2008. View Article : Google Scholar : PubMed/NCBI
13	Granholm S, Henning P and Lerner UH: Comparisons between the effects of calcitonin receptor-stimulating peptide and intermedin and other peptides in the calcitonin family on bone resorption and osteoclastogenesis. J Cell Biochem. 112:3300–3312. 2011. View Article : Google Scholar : PubMed/NCBI
14	Uzan B, de Vernejoul MC and Cressent M: RAMPs and CRLR expressions in osteoblastic cells after dexamethasone treatment. Biochem Biophys Res Commun. 321:802–808. 2004. View Article : Google Scholar : PubMed/NCBI
15	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar
16	Hsu WL, Chen CY, Tsauo JY and Yang RS: Balance control in elderly people with osteoporosis. J Formos Med Assoc. 113:334–339. 2014. View Article : Google Scholar : PubMed/NCBI
17	Manolagas SC and Jilka RL: Bone marrow, cytokines and bone remodeling. Emerging insights into the pathophysiology of osteoporosis. N Engl J Med. 332:305–311. 1995. View Article : Google Scholar : PubMed/NCBI
18	Brunner M, Jurdic P, Tuckerman JP, Block MR and Bouvard D: New insights into adhesion signaling in bone formation. Int Rev Cell Mol Biol. 305:1–68. 2013. View Article : Google Scholar : PubMed/NCBI
19	Roodman GD: Advances in bone biology: The osteoclast. Endocr Rev. 17:308–332. 1996.PubMed/NCBI
20	Roux S and Orcel P: Bone loss. Factors that regulate osteoclast differentiation: An update. Arthritis Res. 2:451–456. 2000. View Article : Google Scholar : PubMed/NCBI
21	Reid IR: Anti-resorptive therapies for osteoporosis. Semin Cell Dev Biol. 19:473–478. 2008. View Article : Google Scholar : PubMed/NCBI
22	Long F: Building strong bones: Molecular regulation of the osteoblast lineage. Nat Rev Mol Cell Biol. 13:27–38. 2011. View Article : Google Scholar : PubMed/NCBI
23	Matsumura S, Hiranuma H, Deguchi A, Maeda T, Jikko A and Fuchihata H: Changes in phenotypic expression of osteoblasts after X irradiation. Radiat Res. 149:463–471. 1998. View Article : Google Scholar : PubMed/NCBI
24	Matsuguchi T, Chiba N, Bandow K, Kakimoto K, Masuda A and Ohnishi T: JNK activity is essential for Atf4 expression and late-stage osteoblast differentiation. J Bone Miner Res. 24:398–410. 2009. View Article : Google Scholar
25	Kim HK, Cho SG, Kim JH, Doan TK, Hu QS, Ulhaq R, Song EK and Yoon TR: Mevinolin enhances osteogenic genes (ALP, type I collagen and osteocalcin), CD44, CD47 and CD51 expression during osteogenic differentiation. Life Sci. 84:290–295. 2009. View Article : Google Scholar : PubMed/NCBI
26	Boyle WJ, Simonet WS and Lacey DL: Osteoclast differentiation and activation. Nature. 423:337–342. 2003. View Article : Google Scholar : PubMed/NCBI
27	Zhao Q, Shao J, Chen W and Li YP: Osteoclast differentiation and gene regulation. Front Biosci. 12:2519–2529. 2007. View Article : Google Scholar
28	Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Lüthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, et al: Osteoprotegerin: A novel secreted protein involved in the regulation of bone density. Cell. 89:309–319. 1997. View Article : Google Scholar : PubMed/NCBI
29	Martin T, Gooi JH and Sims NA: Molecular mechanisms in coupling of bone formation to resorption. Crit Rev Eukaryot Gene Expr. 19:73–88. 2009. View Article : Google Scholar : PubMed/NCBI
30	Khosla S: Minireview: The OPG/RANKL/RANK system. Endocrinology. 142:5050–5055. 2001. View Article : Google Scholar : PubMed/NCBI
31	Kaji H, Kanatani M, Sugimoto T and Chihara K: Statins modulate the levels of osteoprotegerin/receptor activator of NFkappaB ligand mRNA in mouse bone-cell cultures. Horm Metab Res. 37:589–592. 2005. View Article : Google Scholar : PubMed/NCBI
32	Giuliani N, Colla S, Sala R, Moroni M, Lazzaretti M, La Monica S, Bonomini S, Hojden M, Sammarelli G, Barillè S, et al: Human myeloma cells stimulate the receptor activator of nuclear factor-kappa B ligand (RANKL) in T lymphocytes: A potential role in multiple myeloma bone disease. Blood. 100:4615–4621. 2002. View Article : Google Scholar : PubMed/NCBI
33	Udagawa N, Takahashi N, Akatsu T, Tanaka H, Sasaki T, Nishihara T, Koga T, Martin TJ and Suda T: Origin of osteoclasts: Mature monocytes and macrophages are capable of differentiating into osteoclasts under a suitable microenvironment prepared by bone marrow-derived stromal cells. Proc Natl Acad Sci USA. 87:7260–7264. 1990. View Article : Google Scholar : PubMed/NCBI
34	Jimi E, Akiyama S, Tsurukai T, Okahashi N, Kobayashi K, Udagawa N, Nishihara T, Takahashi N and Suda T: Osteoclast differentiation factor acts as a multifunctional regulator in murine osteoclast differentiation and function. J Immunol. 163:434–442. 1999.PubMed/NCBI
35	Abdallah BM, Stilgren LS, Nissen N, Kassem M, Jorgensen HR and Abrahamsen B: Increased RANKL/OPG mRNA ratio in iliac bone biopsies from women with hip fractures. Calcif Tissue Int. 76:90–97. 2005. View Article : Google Scholar